Background Pancreatic ductal adenocarcinoma is a devastating disease with poor outcome,
generally characterized by an excessive stroma component. The purpose of this study was …

Introduction: Despite the increasing financial outlay on cancer research and drug discovery,
many advanced cancers remain incurable. One possible strategy for increasing the approval …

Combinations of gemcitabine and trabectedin exert modest synergistic cytotoxic effects on
two pancreatic cancer cell lines. Here, systems pharmacodynamic (PD) models that …

Gastric cancer (GC) is the third cause of cancer-related mortality worldwide and is often
diagnosed at advanced stages of the disease. This makes the development of more …

In this paper an advanced, clinically oriented multiscale cancer model of breast tumor
response to chemotherapy is presented. The paradigm of early breast cancer treated by …

Culture of cancerous cells in standard monolayer conditions poorly mirrors growth in three-
dimensional architectures typically observed in a wide majority of cancers of different …

Introduction: The research on tumor microenvironment (TME) has recently been gaining
attention due to its important role in tumor growth, progression, and response to therapy …

In tumor engineering, 3D approaches are used to model components of the tumor
microenvironment and to test new treatments. Pancreatic cancers are a cancer of substantial …

Cancer is a complex disease in which both genetic defects and microenvironmental
components contribute to the development, progression, and metastasization of disease …

Background: The current standard of care for pancreatic cancer is weekly gemcitabine
administered for 3 of 4 weeks with a 1-week break between treatment cycles. Maximum …